$2.07
26.99% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US5393192027
Symbol
LIXT
Sector
Industry

Lixte Biotechnology Holdings Inc Stock price

$2.07
+0.47 29.38% 1M
-0.36 14.78% 6M
-0.28 11.91% YTD
-1.03 33.23% 1Y
-14.20 87.28% 3Y
+1.27 158.75% 5Y
+1.27 158.75% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.44 26.99%
ISIN
US5393192027
Symbol
LIXT
Sector
Industry

Key metrics

Market capitalization $4.66m
Enterprise Value $6.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-3.99m
Free Cash Flow (TTM) Free Cash Flow $-3.47m
Cash position $1.64m
EPS (TTM) EPS $-1.78
Short interest 20.44%
Show more

Is Lixte Biotechnology Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Financial data from Lixte Biotechnology Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.14 3.14
30% 30%
-
- Research and Development Expense 0.84 0.84
30% 30%
-
-3.99 -3.99
30% 30%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -3.99 -3.99
30% 30%
-
Net Profit -4 -4
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Lixte Biotechnology Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lixte Biotechnology Holdings Inc Stock News

Neutral
GlobeNewsWire
3 months ago
Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc.
Neutral
GlobeNewsWire
3 months ago
PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. (“Roche”) for treatment of unresponsive (MSI Low) metastatic colorectal cancer.
Neutral
GlobeNewsWire
3 months ago
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial  by Major Pharma Company-
More Lixte Biotechnology Holdings Inc News

Company Profile

Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. The firm uses biomarker technology to identify enzyme targets associated with serious common diseases and designs novel compounds to attack those targets. Its product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.

Head office United States
CEO Bastiaan Baan
Employees 4
Founded 2005
Website www.lixte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today